Toxicity Profiles of Systemic Therapies for Advanced Hepatocellular Carcinoma A Systematic Review and Meta-analysis

被引:14
作者
Griffiths, Christopher D. [1 ]
Zhang, Betty [2 ]
Tywonek, Kasia [1 ]
Meyers, Brandon M. [3 ,4 ]
Serrano, Pablo E. [1 ,4 ,5 ]
机构
[1] McMaster Univ, Dept Surg, Hamilton, ON, Canada
[2] Univ Ottawa, Dept Anesthesia, Ottawa, ON, Canada
[3] McMaster Univ, Dept Oncol, Hamilton, ON, Canada
[4] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada
[5] Juravinski Hosp, Div Gen Surg, 711 Concess St,B3 Off 161, Hamilton, ON L8V 1C3, Canada
关键词
RANDOMIZED PHASE-II; DOUBLE-BLIND; LIVER-TRANSPLANTATION; 2ND-LINE TREATMENT; 1ST-LINE THERAPY; TRANSARTERIAL CHEMOEMBOLIZATION; SORAFENIB TREATMENT; PLUS BEVACIZUMAB; OPEN-LABEL; PLACEBO;
D O I
10.1001/jamanetworkopen.2022.22721
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IMPORTANCE The recent development of targeted therapy and immunotherapy has made neoadjuvant therapy an attractive option for patients with hepatocellular carcinoma (HCC). However, surgeons are concerned that adverse effects of neoadjuvant therapy with these agents could lead to delayed or even cancelled surgeries. OBJECTIVE To summarize the current evidence regarding toxicity profiles for tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) among patients with HCC. DATA SOURCES Medline, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) were searched from January 1990 and December 2021. STUDY SELECTION Single-group, placebo-controlled, and dual-agent clinical trials comparing TKIs and ICIs in patients with HCC were eligible for inclusion. DATA EXTRACTION AND SYNTHESIS Following the Preferred Reporting Items in Systematic Reviews and Meta-analysis guideline, 2 reviewers independently extracted data. A random-effects model was used. MAIN OUTCOMES AND MEASURES The primary outcome was the proportion of patients with clinically significant liver-related adverse events. Secondary outcomes included the proportion of patients who experienced clinically relevant (grade 3 or higher) adverse events and significant adverse events (ie, those that were life threatening, required hospitalization, or prolonged disability) as well as the risk ratio (RR) of these complications. RESULTS Overall, 30 studies with 12 921 patients were included. Patients had a mean (range) age of 62 (18-89) years; a mean (SD) 84%(3) were male; a mean (SD) 82%(16) had Barcelona Clinic Liver Cancer stage C HCC; and a mean (SD) 97%(6) had Childs A cirrhosis. Overall, 21% (95% CI, 16%-26%) of patients receiving TKIs had liver toxic effects compared with 28%(95% CI, 21%-35%) of patients receiving ICIs. Severe adverse events occurred in 46%(95% CI, 40%-51%) of patients receiving TKIs compared with 24%(95% CI, 13%-35%) of patients receiving ICIs. Compared with patients receiving sorafenib, other TKIs were associated with similar rates of liver toxic effects (RR, 1.06; 95% CI, 0.92-1.24) but higher rates of severe adverse events (RR, 1.24; 95% CI, 1.07-1.44). Comparing ICIs with sorafenib, there were similar rates of liver toxic effects (RR, 1.10; 95% CI, 0.86-1.40) and severe adverse events (RR, 1.19; 95% CI, 0.95-1.50). CONCLUSIONS AND RELEVANCE In this systematic review and meta-analysis, serious adverse events were lower with ICIs than with TKIs, while liver toxic effects were similar. Combination therapy with novel ICIs is an appealing option in trials of neoadjuvant therapy for patients with HCC, requiring evaluation in preoperative trials.
引用
收藏
页数:14
相关论文
共 60 条
  • [31] Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma
    Kudo, Masatoshi
    Imanaka, Kazuho
    Chida, Nobuyuki
    Nakachi, Kohei
    Tak, Won-Young
    Takayama, Tadatoshi
    Yoon, Jung-Hwan
    Hori, Takeshi
    Kumada, Hiromitsu
    Hayashi, Norio
    Kaneko, Shuichi
    Tsubouchi, Hirohito
    Suh, Dong Jin
    Furuse, Junji
    Okusaka, Takuji
    Tanaka, Katsuaki
    Matsui, Osamu
    Wada, Michihiko
    Yamaguchi, Iku
    Ohya, Toshio
    Meinhardt, Gerold
    Okita, Kiwamu
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 (14) : 2117 - 2127
  • [32] Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis
    Kulik, Laura
    Heimbach, Julie K.
    Zaiem, Feras
    Almasri, Jehad
    Prokop, Larry J.
    Wang, Zhen
    Murad, M. Hassan
    Mohammed, Khaled
    [J]. HEPATOLOGY, 2018, 67 (01) : 381 - 400
  • [33] Anatomical Resection But Not Surgical Margin Width Influence Survival Following Resection for HCC, A Propensity Score Analysis
    Lee, Jung-Woo
    Lee, Young-Joo
    Park, Kwang-Min
    Hwang, Dae-Wook
    Lee, Jae Hoon
    Song, Ki Byung
    [J]. WORLD JOURNAL OF SURGERY, 2016, 40 (06) : 1429 - 1439
  • [34] Lee M, 2019, ANN ONCOL, V30, P875
  • [35] Sorafenib in advanced hepatocellular carcinoma
    Llovet, Josep M.
    Ricci, Sergio
    Mazzaferro, Vincenzo
    Hilgard, Philip
    Gane, Edward
    Blanc, Jean-Frederic
    Cosme de Oliveira, Andre
    Santoro, Armando
    Raoul, Jean-Luc
    Forner, Alejandro
    Schwartz, Myron
    Porta, Camillo
    Zeuzem, Stefan
    Bolondi, Luigi
    Greten, Tim F.
    Galle, Peter R.
    Seitz, Jean-Francois
    Borbath, Ivan
    Haussinger, Dieter
    Giannaris, Tom
    Shan, Minghua
    Moscovici, Marius
    Voliotis, Dimitris
    Bruix, Jordi
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (04) : 378 - 390
  • [36] Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
    Llovet, Josep M.
    Decaens, Thomas
    Raoul, Jean-Luc
    Boucher, Eveline
    Kudo, Masatoshi
    Chang, Charissa
    Kang, Yoon-Koo
    Assenat, Eric
    Lim, Ho-Yeong
    Boige, Valerie
    Mathurin, Philippe
    Fartoux, Laetitia
    Lin, Deng-Yn
    Bruix, Jordi
    Poon, Ronnie T.
    Sherman, Morris
    Blanc, Jean-Frederic
    Finn, Richard S.
    Tak, Won-Young
    Chao, Yee
    Ezzeddine, Rana
    Liu, David
    Walters, Ian
    Park, Joong-Won
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (28) : 3509 - +
  • [37] Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial
    Marron, Thomas U.
    Fiel, Maria Isabel
    Hamon, Pauline
    Fiaschi, Nathalie
    Kim, Edward
    Ward, Stephen C.
    Zhao, Zhen
    Kim, Joel
    Kennedy, Paul
    Gunasekaran, Ganesh
    Tabrizian, Parissa
    Doroshow, Deborah
    Legg, Meredith
    Hammad, Ashley
    Magen, Assaf
    Kamphorst, Alice O.
    Shareef, Muhammed
    Gupta, Namita T.
    Deering, Raquel
    Wang, Wei
    Wang, Fang
    Thanigaimani, Pradeep
    Mani, Jayakumar
    Troncoso, Leanna
    Tabachnikova, Alexandra
    Chang, Christie
    Akturk, Guray
    Buckup, Mark
    Hamel, Steven
    Ioannou, Giorgio
    Hennequin, Clotilde
    Jamal, Hajra
    Brown, Haley
    Bonaccorso, Antoinette
    Labow, Daniel
    Sarpel, Umut
    Rosenbloom, Talia
    Sung, Max W.
    Kou, Baijun
    Li, Siyu
    Jankovic, Vladimir
    James, Nicola
    Ham, Sara C.
    Cheung, Hung Kam
    Sims, Jennifer S.
    Miller, Elizabeth
    Bhardwaj, Nina
    Thurston, Gavin
    Lowy, Israel
    Gnjatic, Sacha
    [J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (03): : 219 - 229
  • [38] MD Anderson Cancer Center, AT BEV SURG TREATM R
  • [39] Immune-related adverse events with immune checkpoint blockade: a comprehensive review
    Michot, J. M.
    Bigenwald, C.
    Champiat, S.
    Collins, M.
    Carbonnel, F.
    Postel-Vinay, S.
    Berdelou, A.
    Varga, A.
    Bahleda, R.
    Hollebecque, A.
    Massard, C.
    Fuerea, A.
    Ribrag, V.
    Gazzah, A.
    Armand, J. P.
    Amellal, N.
    Angevin, E.
    Noel, N.
    Boutros, C.
    Mateus, C.
    Robert, C.
    Soria, J. C.
    Marabelle, A.
    Lambotte, O.
    [J]. EUROPEAN JOURNAL OF CANCER, 2016, 54 : 139 - 148
  • [40] Moher D, 2009, BMJ-BRIT MED J, V339, DOI [10.1186/2046-4053-4-1, 10.1136/bmj.b2535, 10.1136/bmj.i4086, 10.1136/bmj.b2700, 10.1016/j.ijsu.2010.07.299, 10.1016/j.ijsu.2010.02.007, 10.1371/journal.pmed.1000097]